We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| YM Bio. Com Shs | YMBA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 75.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 75.00 |
| Top Posts |
|---|
Posted at 27/8/2009 17:22 by dutch alert Hi AnalcimeOn Canada symbol YM On US symbol YMI Also on Germany but I have no symbol of that Also quoted in London symbol YMBA Liquidity is best in US On the run again today. I am happy. |
Posted at 02/9/2007 00:15 by rambutan2 YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial ofnimotuzumab in children with inoperable, recurrent brain cancer MISSISSAUGA, ON, Aug. 30 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. ("YM-USA") has been cleared by the US Food and Drug Administration (FDA) to initiate a Phase II trial investigating nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG), a form of inoperable, treatment-resistant brain cancer. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Eight leading US pediatric clinical centers will be participating in the study. YM BioSciences previously announced that it had received a No Objection Letter from Health Canada in June 2007 to initiate this single-arm trial, which will enrol 44 patients with DIPG who will be treated with nimotuzumab as monotherapy. This is the first occasion, to the knowledge of the Company, in which a clinical trial has been cleared by the FDA for a drug of Cuban origin.Clearance for importation of nimotuzumab into the US for this trial was authorized by a Special License issued to YM-USA by the US Treasury Department's Office of Foreign Assets Control (OFAC). Nimotuzumab has already been administered to a number of children in the US under licenses from the US Treasury Department and under single-patient INDs from the FDA. "The clearance of this US IND by the FDA is a significant step in the development of nimotuzumab," said David Allan, Chairman and CEO of YM BioSciences. "In addition to the US investigatory sites, the global development program for nimotuzumab includes ongoing and planned clinical trials involving this and various other indications of cancer in Canada, Europe, Japan, Korea, Singapore, India, Argentina, and Brazil." The trial design is based on a previous trial conducted in Germany. In that trial, which was the subject for an oral presentation at ASCO 2007, eight of 21 children with recurrent DIPG had a clinical benefit from treatment with nimotuzumab as monotherapy - one Partial Response (PR) and seven Stable Disease (SD) were reported in 21 patients, at the end of the induction phase at the eighth week. Those eight patients continued on maintenance therapy and, at week 21, three patients were declared PR and one was evaluated SD. No reports of OR in this patient population has, to the knowledge of the Company, been previously reported. The primary endpoint of the current trial is Response Rate, with a target of 15%, and recruitment is expected to be completed within approximately 18 months from initiation. The principal investigatory site is the Hospital for Sick Children in Toronto, Canada where Drs. Eric Bouffet, Sylvain Baruchel, and Ute Bartels lead the international program. The US investigatory sites at which the trial will be conducted include leading pediatric neuro-oncology centers that are members of the "POETIC" consortium (Pediatric Oncology Experimental Therapeutics International Consortium). Members of POETIC include Vanderbilt Children's Hospital/Vanderbilt- |
Posted at 09/7/2007 23:53 by rambutan2 YM BioSciences announces preclinical data confirming nimotuzumab binds to theEGF receptor and potentiates radiotherapy MISSISSAUGA, ON, July 9 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a study presented by investigators from Kinki University School of Medicine and Kyoto University at the 11th meeting of The Japanese Association for Molecular Target Therapy of Cancer held on July 5-6, 2007 demonstrated the increased radiosensitivity of human NSCLC cell lines in the presence of nimotuzumab both in vitro and in vivo. The study also confirms previous observations that nimotuzumab inhibits ligand-dependent EGF receptor downstream signaling. Daiichi Sankyo Co., Ltd is the licensee for nimotuzumab in Japan. In addition, YM BioSciences announced that a paper on the structure of nimotuzumab entitled 'Modeling the interaction between the anti-tumor antibody h-R3 and its target, the epidermal growth factor receptor' was presented at the 11th annual meeting of the SBNet (Structural Biology Network), held on June 15-18, 2007 in Tallberg, Sweden. The paper demonstrated that nimotuzumab specifically competes with cetuximab for binding to the EGF receptor. The authors noted that, "According to our models, nimotuzumab inhibits the EGFr signaling both by inhibiting the binding of EGF to domain III of EGFr and by a conformational change of EGFr that is necessary to shape the EGF binding site." "These two studies provide independent confirmation of earlier research indicating that nimotuzumab directly binds to the EGF receptor," said Dr. Igor Sherman, Director of Clinical Research at YM BioSciences. "The very rare incidence, in patients treated with nimotuzumab, of the commonly seen side-effects of EGFr-targeting therapy, such as rash and diarrhea, has raised questions about whether nimotuzumab is truly interacting with the EGF receptor. The data presented at SBNet provides further evidence that nimotuzumab binds to the receptor, while the independent data from Kinki and Kyoto demonstrated the synergistic effect of nimotuzumab and radiation on cancer cells and inhibition of EGFr down-stream signaling in the presence of nimotuzumab." "We conclude that nimotuzumab behaves no differently than the other EGFr-targeting antibodies and that the limited and rare incidences of the debilitating side-effects that are commonly seen with other antibodies and small molecules targeting the tyrosine kinase pathway indicates that nimotuzumab has the prospect of being "best-in-class" without compromised efficacy," said David Allan, Chairman and CEO of YM BioSciences. |
Posted at 05/2/2006 14:39 by rambutan2 well, the above article has certainly done its job and attracted a bit more attention in north america. ym/ymi/ymba ended the week at all time highs on its respective mkts. |
Posted at 30/1/2006 01:44 by rambutan2 serratia, re ot:has had some heavyweight vc backing. but bio listings have had a tendency to drop after coming to mkt, so will leave alone for time being. re ymba summary. have just tried but failed to do a quick sum up. just doesn't work beyond a v basic view that mkt cap is too small for co with a phase III cancer drug, with lower failure risk than usual, reporting first results mid 06 and with fda permission to finish there and then if they good enough. beyond that it has a v interesting cuban developed humanized, EGF receptor-targeting monoclonal antibody, called nimotuzumab, which is in various trials around the world. they are also have a cancer pain drug which is in trials. etc etc etc etc... to my mind the mkt cap doesn't reflect any of this fully and therefore offers the chance for the shareprice to multiply on favourable results/investor recognition. sorry, there's no way round it, you need to carefully go through their website and the other sources to try and get ones head round it. |
Posted at 18/9/2005 14:27 by rambutan2 following a request, here's a summary of its main stuff and where ymba is up to with it (courtesy of randychub 31/08)...The phase 3 tesmilifene trial will get a early look in the middle of next year. The first phase 3 trial showed a 143% increase in survival for this group of patients. This is why I invested here. The other main drug is theracim. A knock off of imclones drug erbitux, without the rash. We have not seen enough completed trial data to know the efficacy of this drug yet but we have already seen H&N data similiar to erbitux. It is already approved in china for h&n cancer. This drug has also shown efficacy in pontine gliomas, a brain cancer that is very hard to treat. If this drug continues to show efficacy it will also greatly improve the value of this company. We are waiting for the emea to give the go ahead on 2 phase 3 brain cancer trials and a phase 3 H&N cancer trial. We are also expecting pancreatic cancer data soon. Check out this link and if you have any questions when your done, fire away. Randy and a reminder re what % royalties ymba pay on these in-licensed drugs... Tesmilifene royalties - we pay 4.16 percent. YM owns all rights in US and EU. Theracim - Oncoscience pays YM 30% (estimate) YM owns all rights in the US YM get royalties from cancervax for a egf vaccine. (and dont forget partners who will pay royalties and help develop these drug in other indications lowering the development costs for ymba.) |
Posted at 21/12/2004 13:48 by rambutan2 Best news source is: TSX - YM: AMEX - YMI: AIM - was YMBA but now delisted ym has always been an undervalued oddity (see bottom links for some background and links to cuba) but in 2004 year things have really started to come to fruition as the drugs delivered, money came in and a big deal was signed with cancercax. now could be a good time to buy into a very promising future. aim trades are zilch but tight spread on tsx and it is eligible for an isa (see iaim thread). 24/02/06: The current total float including unexercised options and warrants is 65.5 million. (but do check!) their website: overview of phase III cancer drug: european partner for cuban cancer drug nimotuzumab: and a view of the drug (then theracim, now called nimotuzumab, itself... 12/22/2004 Merriman notes and $8-$12 target 13:47 YMI YM BioSciences: Color on TheraCIM data - Merriman (2.61 +0.11) Merriman notes that yesterday YMI announced preliminary results from a randomized phase II trial conducted by its licensor in Cuba, and says TheraCIM may be better than equivalent to Erbitux. Notably, there was no evidence of skin rash, which has been seen with all other EGF receptor-blocking agents and has previously been assumed to be inseparable from efficacy. While survival data will be needed in order to compare these impressive tumor response results with those of Erbitux radiation therapy in head and neck cancer, firm believes that increasing visibility of the co's valuable pipeline could catalyze gains in the stock over the next 12-18 months toward $8-$12, a valuation more closely in-line with peers. also, indian cuban licencee (biomab = nimotuzumab ie Biomab®, an anti EGFR antibody is in the final stages of Phase IIb clinical trials and expects to file for fast track approval in India by the year end.) lse rns: US board: Canadian board: Enthusiasts board: Conference calls: from canaccord, july 04... YM BioSciences (YM : TSX : C$3.50) - Buy - Target: C$5.20 Karl Keegan Comment: YM's Cuban uncertainty removed? The US Treasury has approved the licensure of two of YM's preclinical compounds to CancerVax. Approval of the deal is important because the two products originate in Cuba. This is the first time that Cuban originated compounds have been licensed to a US company, and means that the products can be sold in the US if successfully developed. The approval has wider implications for YM, as it may mean that TheraCIM, a later stage antibody in Phase 2 trials (which is also Cuban) may now be up for US licensure. We believe that today's announcement removes a significant degree of uncertainty for the stock, and it may open up the US market for more of the pipeline. We maintain our BUY rating and C$5.20 target price. NOTE: more recent canaccord notes are available on advfn research bit of background... The current cancer research at CIM is a joint project between the Cuban government and YM Biosciences Inc, an Ontario-based firm... |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
